Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 43, Issue 11, 2004, Pages 1387-1396

  Geller, Daniel A ^a,e,g   Wagner, Karen Dineen ^b,e,f   Emslie, Graham ^c,e,f   Murphy, Tanya ^d   Carpenter, David J ^e   Wetherhold, Erica ^e   Perera, Phil ^e   Machin, Andrea ^e,f   Gardiner, Christel ^e,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Obsessive compulsive disorder; Paroxetine; Pediatric; Selective serotonin reuptake inhibitor

Indexed keywords

PAROXETINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; AGITATION; APPETITE DISORDER; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HEADACHE; HOSTILITY; HUMAN; HYPERKINESIA; INJURY; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MULTICENTER STUDY; NAUSEA; NEUROSIS; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUICIDAL BEHAVIOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 6944234948     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000138356.29099.f1     Document Type: Article

References (32)

1. American Academy of Child Adolescent Psychiatry (1998), Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 37:27S-45S
2. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Press
3. Carpenter DJ, Geller DA, Biederman J, Wagner K, Emslie G (2001), Comorbid psychiatric illness and response to paroxetine in pediatric OCD. In: Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry, Honolulu
4. Cook EH, Wagner KD, March JS et al. (2001), Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 40:1175-1181
5. Douglass HM, Moffitt TE, Dar R, McGee R, Silva P (1995), Obsessive-compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors. J Am Acad Child Adolesc Psychiatry 34:1424-1431
6. Dunbar G, Steiner M, Bushnell WD, Gergel I, Wheadon DE (1995), Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine. Eur Neuropsychopharmacol 5:372
7. Emslie GJ, Wagner K, Carpenter D, Riddle M, Thienemann M (1999), Efficacy and safety of paroxetine in the treatment of children and adolescent patients with OCD. In: Proceedings of the American College of Neuropsychopharmacology Annual Meeting, Acapulco
8. Flament MF, Whitaker A, Rapoport JL et al. (1988), Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27:764-771
9. Geller D, Biederman J, Emslie G, Carpenter D (2001a), Comorbid psychiatric illness and response to treatment in pediatric OCD. In: Proceeding of the American Psychiatric Association Annual Meeting, New Orleans
10. Geller DA, Biederman J, Stewart ES et al. (2003), Which SRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive compulsive disorder. Am J Psychiatry 160:1919-1928
11. Geller DA, Hoog SL, Heiligenstein JH et al. and the Fluoxetine Pediatric OCD Study Team (2001b), Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 40:773-779
12. Hanna GL (1995), Demographic and clinical features of obsessive-compulsive disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 34:19-27
13. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N (1996), Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present Lifetime Version. Pittsburgh: University of Pittsburgh, Western Psychiatric Institute and Clinic
14. March JS, Biederman J, Wolkow R et al. (1998), Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280:1752-1756
15. Montgomery SA, Bullock T, Fineberg N (1991), Serotonin selectivity for obsessive compulsive and panic disorders. J Psychiatry Neurosci 16:30-35
16. Montgomery SA (1996), Long-term management of obsessive-compulsive disorder. Int Clin Psychopharmacol 11:23-29
17. Montgomery SA, McIntyre A, Osterheider M et al and The Lilly European OCD Study Group (1993), A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 3:143-152
18. National Institute of Mental Health (1985), CGI (Clinical Global Impression) Scale-NIMH. Psychopharmacol Bull 21:839-844
19. Pauls DL, Alsobrook JP, Goodman W, Rasmussen S, Leckman JF (1995), A family study of obsessive-compulsive disorder. Am J Psychiatry 152:76-84
20. Piccinelli M, Pini S, Bellantuono C, Wilkinson G (1995), Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 166:424-443
21. Riddle MA, Reeve EA, Yaryura-Tobias JA et al. (2001), Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222-229
22. Riddle MA, Scahill L, King R et al. (1990), Obsessive compulsive disorder in children and adolescents: phenomenology and family history. J Am Acad Child Adolesc Psychiatry 29:766-772
23. Rosenberg DR, Stewart CM, Fitzgerald KD, Tawile V, Carroll E (1999), Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 38:1180-1185
24. Scahill L, Riddle MA, McSwiggin-Hardin M et al. (1997), Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844-852
25. Startup M, Jackson MC, Bendix S (2002), The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol 41:417-422
26. The World Medical Association (1996), Declaration of Helsinki: ethical principles for medical research involving human subjects. In: Proceedings from the 48th WMA General Assembly, Somerset West, Republic of South Africa
27. Thomsen PH, Ebbesen C, Persson C (2001), Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry 40:895-902
28. Valleni-Basile LA, Garrison CZ, Jackson KL et al. (1994), Frequency of obsessive-compulsive disorder in a community sample of young adolescents. J Am Acad Child Adolesc Psychiatry 33:782-791
29. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL (2002), Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 62:655-703
30. Wheadon DE, Bushnell WD, Steiner M (1993), A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. In: Abstracts: 32nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu
31. Zohar J, Judge R (1996), Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 169:468-474
32. Zohar J, Kaplan Z, Benjamin J (1993), Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. J Clin Psychiatry 54:385-388